Epstein’s pal returns to biotech, Prasad’s FDA exit part deux, and more news from The Readout
The intersection of high-finance controversy, federal regulatory shifts, and groundbreaking oncological science has created a...
The intersection of high-finance controversy, federal regulatory shifts, and groundbreaking oncological science has created a...
In a move that signals a significant reinforcement of its clinical and strategic leadership, Invivyd,...
In the landscape of 1990s cinema, few thrillers have maintained the cultural footprint and technical...
Moving beyond just LDL, or “bad,” cholesterol, and just statins, the updated recommendations take a...
In the complex intersection of modern politics and clinical science, the United States finds itself...
Jim Wells, a veteran biologist at the University of California, San Francisco, was deep into...
In a landmark shift for international pharmaceutical negotiations, Astellas Pharma has successfully utilized the Trump...
To understand the gravity of this comeback, one must revisit the events of August 2019....
The landscape of American healthcare and biomedical research is currently undergoing a period of profound...
In a joint communication recently distributed to the thousands of clinicians and support staff who...